Asana BioSciences Announces FDA Acceptance of the IND Application for its Novel SYK-JAK Inhibitor for Evaluation in Atopic Dermatitis

LAWRENCEVILLE, NJ, USA I March 16, 2017 I Asana BioSciences, LLC, a clinical stage biopharmaceutical company, today announced that the FDA has accepted the IND application for ASN002, a novel dual SYK-JAK inhibitor, for atopic dermatitis.

The Phase I randomized, double-blind, placebo-controlled, multiple dose escalation study will evaluate the safety and tolerability of ASN002 as well as preliminary efficacy in subjects with moderate to severe atopic dermatitis.

“We are extremely pleased with the efficient execution of our strategy to work on clinically validated targets and develop drugs that are differentiated from the competition,” said Sandeep Gupta, PhD, Founder, President and Chief Executive Officer at Asana BioSciences. Asana is focused on the development of ‘Best-in-Class’ drugs designed to offer significant benefit over the existing standards of care and address unmet medical needs. “The successful filing of this IND enables a broader development of ASN002 in autoimmune skin and other diseases and reflects Asana’s expanded scope and capabilities, in addition to our expertise in oncology and hematology drug development,” stated Dr. Gupta. ASN002 is also being evaluated in a Phase I/II clinical trial in patients with non-Hodgkin’s lymphoma and solid tumors.

Asana’s other lead molecules, ASN001 and ASN003, are in Phase I/II clinical trials. ASN001, a novel and highly selective CYP17 inhibitor that does not require prednisone co-administration, targets metastatic castration resistant prostate cancer. ASN003 is a novel and highly selective oral inhibitor of B-RAF and PI3 Kinase enzymes that is being evaluated in patients with advanced solid tumors with RAF or PI3K pathway alterations, e.g. melanoma, colon and lung cancer.

About Asana BioSciences, LLC

Asana BioSciences, LLC, an independent member of the Amneal Alliance of Companies, is a research and development company based in Lawrenceville, NJ, specializing in the discovery and development of new chemical and biological entities. Asana’s portfolio consists of multiple early-stage drug discovery and development candidates in a variety of therapeutic areas, including oncology, pain, dermatology and autoimmune diseases.

SOURCE: Asana BioSciences

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top